Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 24, 2014. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 250,000 Ordinary Shares of 25 pence each.
- Purchase Date: June 24, 2014.
- Price Range: Highest price paid was 1,579.50 pence per share; lowest price paid was 1,563.50 pence per share.
- Treasury Holdings (Settled): 501,889,179 shares (9.38% of total issued share capital).
- Treasury Holdings (Including Unsettled): 502,139,179 shares (10.36% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,849,090,004 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 250,000 shares for treasury. Consequently, the percentage of shares held in treasury increased to 10.36% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in treasury (501,889,179 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.36% held in treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (4,849,090,004 shares in issue excluding treasury).
- Review the price paid per share (1,563.50 to 1,579.50 pence) against market prices on June 24, 2014.